Glenmark Pharmaceuticals Settles US Antitrust Lawsuit for $15.28M

Date: August 11, 2026

Legal Settlement Details:

Glenmark Pharmaceuticals Inc., USA (\"Glenmark USA\"), a subsidiary of Glenmark Pharmaceuticals Ltd., has entered into a settlement agreement with Humana, Inc. (\"Humana\")
Settlement amount: $15.28 million ($15,285,369) including interest
Payment terms: Payable in two installments
Legal context: Resolution of three complaints filed by Humana that were part of consolidated antitrust litigation in the Eastern District of Pennsylvania, U.S.

Background of Litigation:

Since 2016, Glenmark USA has been named in more than 35 complaints alleging violations of federal antitrust laws
Allegations include price-fixing, market allocation, and related anti-competitive conduct concerning generic pharmaceutical products
Plaintiffs include: classes of direct purchasers, endpayers, and indirect purchasers of generic drugs; private, direct-action plaintiffs; and 46 state attorneys general
Plaintiffs allege both individual drug-specific conspiracies and an \"overarching\" conspiracy among many manufacturers of generic drugs in the United States
Glenmark USA has denied all allegations and vigorously defended these matters

Settlement Terms:

Glenmark USA expressly denies each and every allegation made against it
Settlement does not constitute any concession or admission of liability, wrongdoing, or illegality on the part of Glenmark USA
Objective: To resolve dispute and avoid uncertainty

Financial Impact:

The full amount of the payments under the settlement agreements has been provided for in the Company's financials
The settlement will not have a significant impact on the financial position of the Company

Regulatory Compliance:

Disclosure made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended
Reference No.: 45/26-27